Efficacy of low-molecular-weight heparin delivery with the Dispatch catheter following balloon angioplasty in the rabbit iliac artery.
暂无分享,去创建一个
A. Baumbach | K. Karsch | M. Oberhoff | C. Herdeg | E. Blessing | T. Miljak | K. Haase | W. Kunert | B. Horch | A. Bohnet
[1] A. Baumbach,et al. Porous balloon delivery of low molecular weight heparin in the dog coronary artery. , 1996, European heart journal.
[2] N. Fineberg,et al. Vascular injury, repair, and restenosis after percutaneous transluminal angioplasty in the atherosclerotic rabbit. , 1995, Circulation.
[3] P. Serruys,et al. Intracoronary heparin delivery in humans. Acute feasibility and long-term results. , 1995, Circulation.
[4] P. Yock,et al. Intramural delivery of agent via a novel drug-delivery sleeve. Histological and functional evaluation. , 1995, Circulation.
[5] A. Goetz,et al. A new catheter for prolonged local drug application , 1995, Coronary artery disease.
[6] R. Califf,et al. Low Molecular Weight Heparin in Prevention of Restenosis After Angioplasty: Results of Enoxaparin Restenosis (ERA) Trial , 1994, Circulation.
[7] A. Baumbach,et al. Accumulation of macrophages in the arterial vessel wall following experimental balloon angioplasty. , 1994, European heart journal.
[8] R. Virmani,et al. Feasibility and drug delivery efficiency of a new balloon angioplasty catheter capable of performing simultaneous local drug delivery , 1993, Coronary artery disease.
[9] C. Lambert,et al. Local drug delivery catheters: functional comparison of porous and microporous designs , 1993, Coronary artery disease.
[10] Lippincott Williams Wilkins,et al. Does the new angiotensin converting enzyme inhibitor cilazapril prevent restenosis after percutaneous transluminal coronary angioplasty? Results of the MERCATOR study: a multicenter, randomized, double-blind placebo-controlled trial. Multicenter European Research Trial with Cilazapril after Angiopla , 1992, Circulation.
[11] K. Karsch,et al. Inhibition of Cellular Proliferation After Experimental Balloon Angioplasty by Low‐Molecular‐Weight Heparin , 1992, Circulation.
[12] E. Nabel,et al. Site-specific gene expression in vivo by direct gene transfer into the arterial wall. , 1990, Science.
[13] K. Karsch,et al. Time course of smooth muscle cell proliferation in the intima and media of arteries following experimental angioplasty. , 1990, Circulation research.
[14] M. Savage,et al. A controlled trial of corticosteroids to prevent restenosis after coronary angioplasty. M-HEART Group. , 1990, Circulation.
[15] S. Thung,et al. Use of a perforated balloon catheter to deliver concentrated heparin into the wall of the normal canine artery. , 1990, Journal of the American College of Cardiology.
[16] S. Ellis,et al. Effect of 18- to 24-hour heparin administration for prevention of restenosis after uncomplicated coronary angioplasty. , 1989, American heart journal.
[17] J. Hopper,et al. Determinants of restenosis and lack of effect of dietary supplementation with eicosapentaenoic acid on the incidence of coronary artery restenosis after angioplasty. , 1989, Journal of the American College of Cardiology.
[18] L Schwartz,et al. Aspirin and dipyridamole in the prevention of restenosis after percutaneous transluminal coronary angioplasty. , 1988, The New England journal of medicine.